Key Highlights

  • Revenue rose 6.1% to A$48.3 million, profit before tax rose 19.1% to A$8.1 million and net profit after tax rose 14.9% to A$5.5 million for the half-year ended 30 June 2026.
  • An Interim Dividend of 5.0 cents per share, franked at 60%, has an ex-date of 18 September 2026 and a payment date of 2 October 2026.
  • Revenue in the China and Vietnam segment fell, and the company describes China trading conditions as challenging because of regulatory developments and subdued consumer sentiment.

Vita Life Sciences Limited (ASX:VLS), which formulates, packages, sells and distributes vitamins, minerals and food supplements, lodged its Appendix 4D and half-year report for the six months ended 30 June 2026. The company has a 31 December financial year, so the period compares with the half-year to 30 June 2025.

Headline results

Revenue rose 6.1% to A$48.305 million from A$45.544 million. Profit before income tax rose 19.1% to A$8.078 million and net profit after tax rose 14.9% to A$5.541 million, with A$5.559 million attributable to members. Net tangible Assets per security were A$0.92 against A$0.89. The company says profit growth exceeded Revenue growth because of improved operating margins, favourable product mix and cost discipline, and reports a Gross Profit Margin of 63.5%, up from 60.1%.

Dividends

Directors declared a partially franked interim dividend of 5.0 cents per share, 0.5 cents higher than the prior corresponding period, franked at 60% with the unfranked portion sourced from the conduit foreign income account. The ex-dividend date is 18 September 2026, the Record Date 21 September 2026 and the payment date 2 October 2026. The Dividend reinvestment plan is suspended and does not apply. A final 2025 dividend of 9.5 cents, A$5.2 million in total and partially franked, was paid on 10 April 2026.

Regional performance

Australian revenue was A$22.4 million against A$19.6 million, an increase of about 14%, driven by growth in the pharmacy channel and Brand investment in Herbs of Gold. Malaysia and Singapore contributed A$23.4 million against A$21.9 million, up about 7%. The combined China and Vietnam segment was A$2.5 million against A$4.1 million. The company notes growth in Vietnam from a small base, but reduced China sales, and says revenue growth in Australia and Malaysia/Singapore came despite softer consumer sentiment.

China arrangements and segment earnings

The company says China remains challenging due to regulatory change and softer consumer demand, and that new E-commerce distribution arrangements with a strategic partner begin in September 2026 to improve market execution. Segment Earnings before interest and tax were A$3.3 million in Australia, A$5.4 million in Malaysia and Singapore, a loss of A$251,000 in China and Vietnam, and a corporate cost of A$730,000, for a group total of A$7.67 million.

Balance sheet

Cash and cash equivalents were A$33.7 million at 30 June 2026, down from A$35.6 million at the start of the period, and net assets were A$55.7 million against A$56.2 million. Property, plant and equipment was A$12.0 million. The group reports a single Business of complementary medicines, with VMS Operational and VMS Investments segments, and its financial statements were reviewed by the independent auditor.

Segment earnings detail

Earnings before interest and tax were A$7.67 million against A$6.41 million. By segment, Australia earned A$3.31 million against A$2.17 million, Malaysia and Singapore A$5.38 million against A$4.89 million, China and Vietnam recorded a loss of A$251,000 against A$144,000, a separate investment segment recorded a loss of A$40,000 against A$23,000, and corporate costs were A$730,000 against A$484,000. Net interest and bank charges added A$408,000 to profit before tax, and income tax expense was A$2.54 million against A$1.96 million.

Brands and reporting basis

The company names Herbs of Gold and VitaHealth as its key brands, and says retailers' interest in both is growing in Vietnam. Its two operating segments are VMS Operational, covering established brands and markets, and VMS Investments, covering newer markets with low Brand Recognition that need ongoing investment. The half-year report was prepared under AASB 134 and reviewed, and not audited, by the independent auditor.